All information on this website is intended strictly for educational and research purposes only.
The content on OpenPep — including peptide profiles, clinical trial summaries, dosing information, and reconstitution calculators — must not be used for:
OpenPep aggregates publicly available clinical trial data and research. We do not sell, distribute, or recommend any substances. All AI-generated summaries are interpretations of published research and may contain errors.
Retatrutide (GIP/GLP-1/Glucagon triple agonist)
For educational and research purposes only. Not medical advice.
Retatrutide is the most potent weight loss peptide in development. Phase II data showed 24.2% body weight reduction — more than any other anti-obesity agent. The triple-agonist mechanism adds glucagon-mediated thermogenesis to the proven GLP-1/GIP approach.
Best Time
Any time, same day each week
Method
subcutaneous
Frequency
Once weekly
Half-life
~6 days
Cycle Length
Ongoing (clinical trial protocol)
Storage
Refrigerate at 2-8°C.
Published Dosing Ranges
Create an account to access peptide research data.
Contraindications
Create an account to access peptide research data.
Overlapping GLP-1 and GIP receptor agonism. Retatrutide adds glucagon receptor activity. Combining dual/triple agonists risks severe GI distress, hypoglycemia, and unpredictable receptor dynamics.
documentedBoth activate GLP-1 receptors. Retatrutide already provides GLP-1 + GIP + glucagon agonism. Adding semaglutide causes GLP-1 receptor overstimulation with dangerous GI and pancreatic risks.
documentedAnnals of internal medicine 178 (2) :199-217 · 2025-02-01
European journal of preventive cardiology 33 (7) :1210-1217 · 2026-05-15
Journal of diabetes 17 (4) :e70082 · 2025-04-01
Endocrinology, diabetes & metabolism 9 (2) :e70187 · 2026-03-01
European journal of medical research 31 (1) :318 · 2026-01-26
Mechanism of Action
Triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. The glucagon component adds thermogenic fat burning on top of appetite suppression and insulin modulation.
Reported by the community. These may not be supported by clinical evidence and are not medical recommendations.